08:22 AM EDT, 06/30/2025 (MT Newswires) -- Artelo Biosciences ( ARTL ) said Monday the first in-human study of its novel non-opioid analgesic ART26.12 affirmed the promising safety and pharmacokinetic profile previously observed in preclinical studies.

The phase 1 single ascending dose study showed no drug-related adverse events in the blinded dataset, and no tolerability issues or safety signals were detected across multiple assessments, the company said.

Artelo said it expects to proceed to a multiple ascending dose study in Q4 to further assess ART26.12 with repeated dosing over time.

The company's shares were up 136% in recent premarket activity on Monday.